PPAR-α targeting in kidney fibrosis: is BAY PP1 just another renoprotector?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22083634.
- Also identified by DOI 10.1038/ki.2011.299.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interstitial fibrosis plays a major role in the progression of renal diseases. Peroxisome proliferator-activated receptor-α (PPAR-α) ligands are increasingly explored for their potential to reverse or halt tubulointerstitial fibrosis. This Commentary discusses new findings by Boor et al., who show that BAY PP1, a novel PPAR-α agonist, ameliorates renal fibrosis and dysfunction.
Medical subject headings
- 3-Mercaptopropionic Acid
- Fibrosis
- Kidney Diseases
- Peroxisome Proliferator-Activated Receptors
- Pyrimidines